المؤلفون: Ascierto, Paolo A, Dummer, Reinhard, Gogas, Helen J, Flaherty, Keith T, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, de Groot, Jan Willem B, Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D, Robert, Caroline

المصدر: Ascierto, Paolo A; Dummer, Reinhard; Gogas, Helen J; Flaherty, Keith T; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; de Groot, Jan Willem B; Loquai, Carmen; Gollerkeri, Ashwin; Pickard, Michael D; Robert, Caroline (2020). Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. European Journal of Cancer, 126:33-44.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/183844/8/1-s2.0-S095980491930841X-main.pdfTest; info:pmid/31901705; urn:issn:0959-8049

الإتاحة: https://doi.org/10.5167/uzh-18384410.1016/j.ejca.2019.11.016Test
https://www.zora.uzh.ch/id/eprint/183844Test/
https://www.zora.uzh.ch/id/eprint/183844/8/1-s2.0-S095980491930841X-main.pdfTest

المؤلفون: Ascierto, Paolo A., Dummer, Reinhard, Gogas, Helen J., Flaherty, Keith T., Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, de Groot, Jan Willem B., Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D., Robert, Caroline

المساهمون: Pfizer, Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Amgen, Pierre Fabre, Amicus, Boehringer-Ingelheim, NeraCare, Philogen, Sanofi, Neracare, Array BioPharma, Boehringer Ingelheim, LEO Pharma, Hexal, InflaRx, Helsinn, GI Innovation, Immunocore, Incyte, Regeneron, 4SC, AstraZeneca, Merck-EMD, Ultimovacs, Sun Pharma, Johnson&Johnson, Merck Serono, Servier, Biontech

المصدر: European Journal of Cancer ; volume 126, page 33-44 ; ISSN 0959-8049

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.ejca.2019.11.016Test
https://api.elsevier.com/content/article/PII:S095980491930841X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S095980491930841X?httpAccept=text/plainTest

المؤلفون: Gogas, Helen J, Flaherty, Keith T, Dummer, Reinhard, Ascierto, Paolo A, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Sileni, Vanna Chiarion, Dutriaux, Caroline, de Groot, Jan Willem B, Yamazaki, Naoya, Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D, Robert, Caroline

المصدر: Gogas, Helen J; Flaherty, Keith T; Dummer, Reinhard; Ascierto, Paolo A; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Sileni, Vanna Chiarion; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Gollerkeri, Ashwin; Pickard, Michael D; Robert, Caroline (2019). Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. European Journal of Cancer, 119:97-106.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/174049/1/809_Gogas_H._et_al._Adverse_events_associated_with_encorafenib_plus_binimetinib_in_the_COLUMBUS_study_EJC_2019.pdfTest; info:pmid/31437754; urn:issn:0959-8049

الإتاحة: https://doi.org/10.5167/uzh-17404910.1016/j.ejca.2019.07.016Test
https://www.zora.uzh.ch/id/eprint/174049Test/
https://www.zora.uzh.ch/id/eprint/174049/1/809_Gogas_H._et_al._Adverse_events_associated_with_encorafenib_plus_binimetinib_in_the_COLUMBUS_study_EJC_2019.pdfTest

المؤلفون: Gogas, Helen J., Flaherty, Keith T., Dummer, Reinhard, Ascierto, Paolo A., Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Sileni, Vanna Chiarion, Dutriaux, Caroline, de Groot, Jan Willem B., Yamazaki, Naoya, Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D., Robert, Caroline

المساهمون: Array BioPharma, Inc., Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Amgen, Pierre Fabre, BMS, Genentech, Array, MSD, Merck, Amicus, Boehringer-Ingelheim, Boehringer Ingelheim, LEO Pharma, Incyte, Regeneron, 4SC, AstraZeneca, EMD, Pfizer, Philogen, Array BioPharma, Johnson & Johnson, MerckSerono, Almirall-Hermal, Merck-Serono, Pierre-Fabre, SUN, Roche Pharma, Takeda, Servier, Ono Pharmaceutical

المصدر: European Journal of Cancer ; volume 119, page 97-106 ; ISSN 0959-8049

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.ejca.2019.07.016Test
https://api.elsevier.com/content/article/PII:S0959804919304241?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0959804919304241?httpAccept=text/plainTest

المؤلفون: Dummer, Reinhard, Ascierto, Paolo A, Gogas, Helen J, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion-Sileni, Vanna, Dutriaux, Caroline, de Groot, Jan Willem B, Yamazaki, Naoya, Loquai, Carmen, Moutouh-de Parseval, Laure A, Pickard, Michael D, Sandor, Victor, Robert, Caroline, Flaherty, Keith T

المصدر: Dummer, Reinhard; Ascierto, Paolo A; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A; Pickard, Michael D; Sandor, Victor; Robert, Caroline; Flaherty, Keith T (2018). Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, 19(5):603-615.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/151962/1/747_Dummer_R._et_al._Encorafenib_plus_binimetinib_versus_vemurafenib_or_encorafenib_in_patients_Lancet_Oncology_2018.pdfTest; https://www.zora.uzh.ch/id/eprint/151962/8/Dummer_et_al_Lancet_Oncology_13.12.17.pdfTest; info:pmid/29573941; urn:issn:1470-2045

الإتاحة: https://doi.org/10.5167/uzh-15196210.1016/S1470-2045Test(18)30142-6
https://www.zora.uzh.ch/id/eprint/151962Test/
https://www.zora.uzh.ch/id/eprint/151962/1/747_Dummer_R._et_al._Encorafenib_plus_binimetinib_versus_vemurafenib_or_encorafenib_in_patients_Lancet_Oncology_2018.pdfTest
https://www.zora.uzh.ch/id/eprint/151962/8/Dummer_et_al_Lancet_Oncology_13.12.17.pdfTest

المؤلفون: Bhatia, Shailender, Pavlick, Anna C., Boasberg, Peter, Thompson, John A., Mulligan, George, Pickard, Michael D., Faessel, Hélène, Dezube, Bruce J., Hamid, Omid

المصدر: Investigational New Drugs ; volume 34, issue 4, page 439-449 ; ISSN 0167-6997 1573-0646

مصطلحات موضوعية: Pharmacology (medical), Pharmacology, Oncology

الإتاحة: https://doi.org/10.1007/s10637-016-0348-5Test

المؤلفون: Robert, Caroline, Dummer, Reinhard, Flaherty, Keith, Arance, Ana Maria, Groot, Jan Willem De, Garbe, Claus, Gogas, Helen, Gutzmer, Ralf, Krajsová, Ivana, Liszkay, Gabriella, Loquai, Carmen, Mandalà, Mario, Schadendorf, Dirk, Yamazaki, Naoya, Pickard, Michael D., Zohren, Fabian, Edwards, Michelle L., Ascierto, Paolo Antonio

المصدر: Annales de Dermatologie et de Vénéréologie - FMC ; volume 1, issue 8, page A123 ; ISSN 2667-0623

مصطلحات موضوعية: Ocean Engineering, Safety, Risk, Reliability and Quality

الإتاحة: https://doi.org/10.1016/j.fander.2021.09.551Test
https://api.elsevier.com/content/article/PII:S266706232100828X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S266706232100828X?httpAccept=text/plainTest

المؤلفون: Dummer, Reinhard Flaherty, Keith Robert, Caroline Arance, Ana Maria De Groot, Jan Willem Garbe, Claus Gogas, Helen and Gutzmer, Ralf Krajsova, Ivana Liszkay, Gabriella Loquai, Carmen Mandala, Mario Schadendorf, Dirk Yamazaki, Naoya and Pickard, Michael D. Zohren, Fabian Edwards, Michelle L. and Ascierto, Paolo Antonio

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______2127::84362541e99bf7393c88a30c355c1e00Test
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3196673Test

المؤلفون: Sullivan, Ryan J, Weber, Jeffrey, Patel, Sapna, Dummer, Reinhard, Carlino, Matteo S, Tan, Daniel SW, Lebbé, Celeste, Siena, Salvatore, Elez, Elena, Wollenberg, Lance, Pickard, Michael D, Sandor, Victor, Ascierto, Paolo A

الإتاحة: https://doi.org/10.5167/uzh-190352Test
https://www.zora.uzh.ch/id/eprint/190352Test

المؤلفون: Dummer, Reinhard, Sandhu, Shahneen Kaur, Miller, Wilson H., Butler, Marcus O., Blank, Christian U., Munoz-Couselo, Eva, Burris, Howard A., III, Postow, Michael A., Chmielowski, Bartosz, Middleton, Mark R., Berking, Carola, Hassel, Jessica Cecile, Gesierich, Anja, Mauch, Cornelia, Kleha, Joseph, Gollerkeri, Ashwin, Harney, Allison, Pickard, Michael D., Ascierto, Paolo Antonio

مصطلحات موضوعية: ddc:no

العلاقة: Dummer, Reinhard, Sandhu, Shahneen Kaur, Miller, Wilson H., Butler, Marcus O., Blank, Christian U., Munoz-Couselo, Eva, Burris, Howard A., III, Postow, Michael A., Chmielowski, Bartosz, Middleton, Mark R., Berking, Carola, Hassel, Jessica Cecile, Gesierich, Anja, Mauch, Cornelia, Kleha, Joseph, Gollerkeri, Ashwin, Harney, Allison, Pickard, Michael D. and Ascierto, Paolo Antonio (2020). A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2). J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

الإتاحة: https://kups.ub.uni-koeln.de/33320Test/